Spitalul Clinic De Boli Infectioase Si Pneumoftiziologie Victor Babes Craiova
- Address
- Strada Calea Bucuresti Nr. 64 Fost 126, 200515 Craiova, Romania
Respiratory Tract Diseases
At Spitalul Clinic De Boli Infectioase Si Pneumoftiziologie Victor Babes Craiova, the strongest research focus is on respiratory diseases, especially asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis. The studies are mainly designed to test new inhaled or targeted therapies, compare treatment options, and improve control of symptoms and flare-ups.
- Asthma research covering mild, moderate, and severe forms, including eosinophilic and uncontrolled disease
- COPD studies focused on reducing exacerbations and improving lung function
- Idiopathic pulmonary fibrosis research aimed at slowing loss of breathing capacity
This Pneumologie department in Craiova is contributing to clinical trials that seek better long-term management and more effective respiratory care.
Immune System Diseases
The site also conducts research in immune system diseases, with a notable emphasis on asthma as an inflammatory condition. These trials are exploring whether newer therapies can better reduce airway inflammation, prevent worsening disease, and support more stable breathing over time.
- Moderate-to-severe asthma
- Uncontrolled moderate to severe eosinophilic asthma
- Controlled and partly controlled asthma
Overall, the research aims to improve day-to-day disease control and lower the risk of future attacks for patients treated at this hospital.
Virus Diseases
Another important area of research is virus diseases, especially COVID-19 and hepatitis B infection. The trials are evaluating whether new antiviral or immune-based approaches can improve outcomes, reduce complications, and support better disease management.
- COVID-19 studies focused on lowering hospitalization and death in outpatients
- Chronic hepatitis B research examining antiviral and immune response strategies
- Pediatric hepatitis B studies looking at treatment effectiveness and viral control
These investigations reflect the site’s role in addressing both acute and long-term infectious diseases through clinical research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Chiesi Farmaceutici S.p.A.3active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.8trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Spitalul Clinic De Boli Infectioase Si Pneumoftiziologie Victor Babes Craiova
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Beclometasone Dipropionate Anhydrous | 4 | Unknown | 2022-04-22 | 2026-04-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.